News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Roche (RHHBY)'s Avastin Rejected by National Institute for Clinical Excellence (NICE) for Use in Breast Cancer


4/18/2012 7:41:10 AM

Roche Holding AG (ROG)’s Avastin doesn’t meet cost criteria for extending the lives of breast-cancer patients when combined with the chemotherapy drug capecitabine, and shouldn’t be used as a first-line treatment, the U.K. medical-spending regulator said.

An appraisal by the National Institute for Health and Clinical Excellence found it was unclear whether Avastin, also known as bevacizumab, extended overall survival and improved patients’ quality of life more than capecitabine alone, the agency said today in a statement.

Read at Bloomberg
Read at Fox News
Read at News Release
Read at MSN
Read at InPharm.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES